Alzheimer's risk could rise with specific sleep pattern, experts warn
The research from China, published in the journal Alzheimer's & Dementia by the Alzheimer's Association, analyzed the sleep cycles of 128 adults in varying states of cognition.
Advertisement
The study found that the highest occurrence of REM latency — which is when it takes longer for someone to reach the first REM period after drifting off to sleep — was associated with the highest risk of Alzheimer's.
The researchers concluded that prolonged REM latency may serve as a 'novel marker of risk factor' for Alzheimer's disease and related dementias.
Dr. Wendy Troxel, senior behavioral scientist at the RAND Corporation in California, said this study adds to 'growing evidence' that specific sleep features, like prolonged REM sleep, are linked to Alzheimer's biomarkers.
'REM sleep is the stage of sleep when dreams mostly occur, and is critically important for memory consolidation and emotional processing,' Utah-based Troxel, who is also author of 'Sharing the Covers: Every Couple's Guide to Better Sleep,' told Fox News Digital.
Advertisement
This new research aligns with findings from Troxel's own lab, which have shown that other signs of poor sleep health — like shorter duration and poor quality — are associated with worse cognitive function.
'Sleep disruptions may contribute to the buildup of amyloid and tau proteins, key features of Alzheimer's pathology,' the sleep expert said.
5 A new study has found a link between rapid eye movement (REM) sleep and Alzheimer's disease.
amenic181 – stock.adobe.com
'But it's also important to note that the Alzheimer's disease process itself can disrupt sleep, suggesting a bidirectional association between sleep problems and cognitive decline.'
Advertisement
Dr. Giulio Taglialatela, vice president and research institute director of the Brain Health Institute at the University of Texas Medical Branch, reacted to these findings in a separate interview with Fox News Digital.
Taglialatela said it's been 'long understood' that getting a good night's sleep is associated with a lower risk of developing dementia.
'Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle,' he noted.
5 The study found that the highest occurrence of REM latency was associated with the highest risk of Alzheimer's.
Rawpixel.com – stock.adobe.com
Advertisement
'Unfortunately, there is nothing an individual can do to control how long it takes to enter REM sleep,' the expert.'
However, the expert said, the findings provide a 'promising avenue' for predicting the likelihood of someone eventually developing dementia.
'Early intervention in Alzheimer's is essential for delaying its progression, and measuring REM sleep could be a marker to indicate who may be a candidate for treatment even before they start to show impaired cognitive function,' Taglialatela said.
Potential limitations
5 'Our brains use sleep to clear out toxic proteins, like those associated with Alzheimer's, and these results show that the cleaning mechanism is less effective when it takes someone longer to enter the REM cycle,' Dr. Giulio Taglialatela noted.
sudok1 – stock.adobe.com
The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, 'and thus the direction of the association cannot be determined.'
The sample size was also relatively small, and the researchers only focused on one specific type of tau protein.
There is also the possibility that monitoring sleep in a clinical setting may introduce 'environmental disturbances,' impacting sleep measurement accuracy, the researchers noted. 'Future studies will benefit from research in real-world home settings,' they wrote.
Tips for sleep improvements
5 The study did have some limitations, the researchers acknowledged – primarily that it was cross-sectional, 'and thus the direction of the association cannot be determined.'
LIGHTFIELD STUDIOS – stock.adobe.com
Advertisement
While these findings are important, Troxel said, she encourages individuals to not allow the information to be 'another source of worry that keeps you awake at night.'
'Avoid the tendency to become overly fixated on metrics like REM sleep percentage or latency from consumer sleep trackers, as they have limited accuracy in determining sleep architecture,' she cautioned. 'Obsessing on such data can increase anxiety, which is a powerful sleep disruptor.'
Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here!
The best approach is to focus on the foundations of good sleep health, the expert said.
Advertisement
Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to Troxel.
5 Adults should strive for seven to nine hours of shuteye and should maintain consistent sleep and wake times, according to experts.
Satawat – stock.adobe.com
'Minimize common disruptors such as excessive caffeine and alcohol, which are known to fragment REM sleep, [as well as] screen use before bedtime,' she added.
Advertisement
'Focusing on these core sleep habits is the most effective and evidence-based way to support the brain and overall health.'
Taglialatela also encourages individuals to focus on creating an 'ideal sleep environment' while maintaining 'good bedtime habits' to reduce the risk of developing Alzheimer's.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
an hour ago
- Forbes
UK Announces Deal With OpenAI To Augment Public Services And AI Power
UK and OpenAI Announce a new MOU OpenAI and the United Kingdom's Department for Science, Innovation and Technology signed a joint memorandum of understanding yesterday that sets out an ambitious joint plan to put OpenAI's models to work in day-to-day government tasks, to build new computing hubs on British soil, and to share security know-how between company engineers and the UK's AI Safety Institute. The agreement is voluntary and doesn't obligate the UK in any exclusive manner, yet the commitments are concrete: both sides want pilot projects running inside the civil service within the next twelve months. Details of the Joint MOU The memorandum identifies four key areas of joint innovation. It frames AI as a tool to raise productivity, speed discovery and tackle social problems, provided the public is involved so trust grows alongside capability. The partners will look for concrete deployments of advanced models across government and business, giving civil servants, small firms and start-ups new ways to navigate rules, draft documents and solve hard problems in areas such as justice, defence and education. To run those models at scale, they will explore UK-based data-centre capacity, including possible 'AI Growth Zones,' so critical workloads remain onshore and available when demand peaks. Finally, the deal deepens technical information-sharing with the UK AI Security Institute, creating a feedback loop that tracks emerging capabilities and risks and co-designs safeguards to protect the public and democratic norms. OpenAI also plans to enlarge its London office, currently at more than 100 staff, to house research and customer-support AI CEO Sam Altman has long been interested in the UK as a region for AI development because of the UK's long history in AI research, most notably starting with Alan Turing. 'AI will be fundamental in driving the change we need to see across the country, whether that's in fixing the NHS, breaking down barriers to opportunity or driving economic growth,' said UK Technology Secretary, Peter Kyle. 'That's why we need to make sure Britain is front and centre when it comes to developing and deploying AI, so we can make sure it works for us.' Altman echoed the ambition, calling AI 'a core technology for nation building' and urging Britain to move from planning to delivery. The Increasing Pace of Governmental AI Adoption and Funding Universities in London, Cambridge and Oxford supply a steady stream of machine-learning talent. Since the Bletchley Park summit in 2023, the UK has positioned itself as a broker of global safety standards, giving investors a sense of legal stability. And with a sluggish economy, ministers need a credible growth story; large-scale automation of paperwork is an easy pitch to voters. The UK offers scientists clear rules and public money. The UK government has already promised up to £500 million for domestic compute clusters and is reviewing bids for 'AI Growth Zones'. Three factors explain the timing. The UK is not alone in its AI ambitions. France has funnelled billions into a joint venture with Mistral AI and Nvidia, while Germany is courting Anthropic after its own memorandum with DSIT in February. The UK believes its head start with OpenAI, still the best-known brand in generative AI, gives it an edge in landing commercial spin-offs and high-paid jobs. Risks that could derail the plan Kyle knows that any mis-step, such as an AI bot giving faulty benefit advice, could sink trust. That is why the memorandum pairs deployment with security research and reserves the right for civil-service experts to veto outputs that look unreliable. The UK has had a long history with AI, and the risks posed by lack of progress. Notably, the infamous Lighthill report in 1973 was widely credited with contributing the first 'AI Winter', a marked period of decline of interest and funding in AI. As such, careful political consideration of AI is key to ensuring ongoing support. Public-sector unions may resist widespread automation, arguing that AI oversight creates as much work as it saves. Likewise there is widespread concern of vendor lock-in with the deal with OpenAI. By insisting on locally owned data centres and keeping the MOU open to additional suppliers, ministers hope to avoid a repeat of earlier cloud contracts that left sensitive workloads offshore and pricy relationships locked in. Finally, a single headline error, such as a chatbot delivering wrong tax guidance, for instance, could spark calls for a pause. However, the benefits currently outweigh the risks. No department stands to gain more than the UK's National Health Service, burdened by a record elective-care backlog. Internal modelling seen by officials suggests that automated triage and note-summarisation tools could return thousands of clinical hours each week. If early pilots succeed, hospitals in Manchester and Bristol will be next in line. And OpenAI is not new to the UK government. A chatbot for small businesses has been live for months, and an internal assistant nicknamed 'Humphrey' now drafts meeting notes and triages overflowing inboxes. Another tool, 'Consult,' sorts thousands of public submissions in minutes, freeing policy teams for higher-level work. The new agreement aims to lift these trials out of the margins and weave them more fully into the fabric of government. What's Next Joint project teams will start by mapping use-cases in justice, defence and social care. They must clear privacy impact assessments before live trials begin. If those trials shave measurable hours off routine tasks, the Treasury plans to set aside money in the 2026 Autumn Statement for a phased rollout. UK's agreement with OpenAI is an experiment in modern statecraft. It tests whether governmental organizations can deploy privately built, high-end models while keeping control of data and infrastructure. Success would mean delivering the promised benefits while avoiding the significant risks. Failure would reinforce arguments that large language models remain better at publicity than at public service.
Yahoo
2 hours ago
- Yahoo
Scientists Discovered a New Alzheimer's Warning Sign—and It Has to Do With Your Sleep
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Alzheimer's disease is a devastating condition that impacts millions of families around the world. But scientists are still trying to pinpoint the elements that go into why some people develop Alzheimer's disease and others don't. Now, a new study suggests that your sleep patterns may play a role. The study, which was published in the journal Alzheimer's & Dementia, specifically looked at the relationship between REM sleep and Alzheimer's disease. But what's the link between the two and, more importantly, how can you use this information to lower your risk of developing Alzheimer's disease? A neurologist explains. Meet the expert: W. Christopher Winter, MD, a neurologist and sleep medicine physician with Charlottesville Neurology and Sleep Medicine and host of the podcast. What did the study find? For the study, researchers looked at how long it took 123 people to reach rapid eye movement (REM) sleep for the first time after falling asleep, as well as several biomarkers linked to Alzheimer's disease. (REM sleep is a stage of sleep where your eyes move quickly and you dream, per the Cleveland Clinic. It's important for learning and memory, too.) Of the participants, 64 had Alzheimer's disease and 41 had mild cognitive impairment, while the others had normal cognitive function. All of the participants did a sleep study, as well as scans for biomarkers that indicated Alzheimer's. The researchers discovered that people who took longer to get to the REM stage of sleep were more likely to have biomarkers of Alzheimer's disease. Is there a relationship between sleep and Alzheimer's? The relationship between sleep and Alzheimer's disease is still being explored. The Alzheimer's Society notes that people living with dementia tend to have sleep issues, but the evidence is currently unclear on whether poor sleep is a risk factor for the disease. However, some research suggests that poor sleep could raise your risk of Alzheimer's. A study published in November found that 35 percent of people who were considered poor sleepers (and felt excessively tired during the day as a result) went on to develop motoric cognitive risk syndrome (MCR), which is considered a precursor to dementia. 'Poor sleep quality has been linked to Alzheimer's disease,' says W. Christopher Winter, MD, a neurologist and sleep medicine physician with Charlottesville Neurology and Sleep Medicine and host of the podcast. 'Conversely, individuals who sleep well, and get consistent amounts of sleep on a consistent schedule, seem to reduce their risk of cognitive impairment.' Can a lack of REM sleep increase my risk of Alzheimer's? It's hard to say for sure at this point. While the researchers concluded that more studies are needed, they also said a slower movement to REM sleep could serve as a 'potential marker' for Alzheimer's disease. Given that good sleep is linked to good overall health, it can't hurt to try to improve your sleep. How can I get more REM sleep? Most people go through four to six sleep cycles a night, and REM sleep is part of that. Unfortunately, you can't dictate the stages of sleep you enter and when. What you can do is try to focus on getting good sleep, period. Winter offers up these tips to help support good sleep: Have a set bedtime and wake time, and do your best to stick to it. Limit alcohol and caffeine, especially avoiding caffeine later in the day. Try to be physically active, and aim to work out in the mornings to support your body's natural sleep/wake cycle. Create a good, consistent bedtime routine that helps you wind down for the evening. Be wary of sleep aids. 'Ironically, some sleep aids affect REM sleep,' Winter says. How can I reduce my risk of Alzheimer's? Researchers don't know exactly what causes Alzheimer's disease and dementia, making it tough to know for sure how to prevent it. But the Centers for Disease Control and Prevention (CDC) recommends doing these things to help lower your risk: Be physically active Try to prevent or manage diabetes Manage your blood pressure Try to prevent or correct hearing loss Try to limit or avoid drinking alcohol Try to limit or avoid smoking If you're struggling with sleep, Winter says it's important to consult with a healthcare professional sooner rather than later. They should be able to do a sleep study—which can give you more information on what's behind your sleep issues—and make personalized recommendations from there. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Forbes
2 hours ago
- Forbes
Breakthroughs Changing The Diagnosis And Treatment Of Alzheimer's
Jerry Klauer, an Alzheimer's patient who received a recently approved therapy to treat the disease, ... More pictured last year in Florida with his wife Jana, a retired physician. In 2012, Phyllis Barkman Ferrell experienced a profound irony. The longtime veteran of Eli Lilly was leading a team preparing to launch a groundbreaking molecule to treat Alzheimer's when her own father was diagnosed with the disease. He became one of approximately 500,000 people diagnosed in the United States with the disease that year. Globally, over 10 million cases of dementia are diagnosed each year, with Alzheimer's contributing a large portion of the burden. Though Ferrell had rare access to top leaders working in the field, her father's path to a diagnosis was not straightforward, and never actually became clear. He spent a week in the hospital and endured a lumbar puncture and the insertion of a shunt in his brain. A PET scan, which can detect abnormal changes in the brain consistent with Alzheimer's disease, cost $10,000 and was not covered by insurance. When Ferrell asked a resident at the hospital to give her father an amyloid test, the resident responded, 'What's an amyloid test?' Amyloid refers to a protein that misfolds and accumulates pathological deposits in the brains of people with Alzheimer's disease. 'Imagine if I could have given him a blood test to see if he had amyloid,' says Ferrell, 'rather than a lumbar puncture and brain surgery?' In fact, that is exactly what has become available – along with two disease-modifying therapies. The New Alzheimer's Workup Today, if patients present with symptoms of memory loss to their primary care provider, they can be referred to a workup for Alzheimer's at a memory clinic with tools that weren't available even three years ago. 'We just got on base at a game that nobody had ever gotten a hit before,' says Ferrell, who now works with the Davos Alzheimer's Collective, a global public health initiative working to improve patients' access to the new innovations. In the new workup, patients can take a digital cognitive assessment, which compares their performance to a standard database. If the patient has a reasonably high chance of having Alzheimer's based on their presentation, then a blood-based biomarker test can be 'very good' at informing the diagnosis, says Dr. Greg Cooper, chief of adult neurology and director of the Memory Center at Norton Neuroscience Institute in Louisville, Kentucky. Jeff Burns, neurologist who co-directs the Alzheimer's Disease Research Center at the University of Kansas in Kansas City, has seen clinicians in his health system order 600 of the blood tests in 11 weeks since the in-house test became available, a sign of their high demand. 'They're very useful in the right context,' he says, adding that he would like to see their use increase in primary care, since memory clinics are 'overloaded' with patients. In Kansas, for instance, there's only one such clinic in the state. If the blood test is positive, patients can go for an insurance-approved PET scan or spinal fluid testing to determine if they are eligible for the new drugs. If the amyloid diagnosis is confirmed, patients can be prescribed one of two monoclonal antibodies, both FDA-approved in 2023, that can slow disease progression by targeting and removing pathological amyloid deposits in the brain. 'It's the first time we can actually alter the trajectory of disease,' Cooper says. A Patient Story Jerry Klauer, 83, is living proof of this remarkable paradigm shift. Several years ago, his wife Jana, a retired physician, began noticing a troubling change in his memory. He was forgetting dates and plans, though he had been impeccably on time before. He also struggled to recall recent events, and his driving became unsafe. Through a connection at the Alzheimer's Drug Discovery Foundation, Jerry got diagnosed with Alzheimer's after a positive blood-based biomarker test and a PET scan confirmed high amyloid buildup. He then became eligible to join a clinical trial of one of the monoclonal antibodies (which has since been FDA-approved). 'I was very fortunate to get into the program early,' says Jerry, who is a co-founder of the Wall Street boutique investment firm Gerard Klauer Mattison and Company. Though he acknowledges that the drug is not a cure, it reduced his amyloid and improved his symptoms. Before he started the drug, his amyloid had to be in a certain high range to qualify. Now, his amyloid measures in the normal range. 'He's stable,' Jana says. 'If he wasn't doing this, he would be getting worse. Is his memory what it was when he was 30 or 40 years told? No, but he lives his life. It's a wonderful life.' Early Intervention Matters Jerry's Alzheimer's disease was not very advanced when he started the monoclonal antibody. That is when the medicine can be most effective. 'In the past,' says Greg Cooper, 'although wrong, people had a nihilistic approach, saying why should I be in a hurry to get a diagnosis? Now the urgency for a diagnosis is compelling.' A major question the field is seeking to answer is just how early does it pay to get diagnosed? The pathological changes in the brain from Alzheimer's start 15 to 20 years before symptoms begin. Current clinical trials that read out in 2027 are testing whether patients who have confirmed amyloid, but zero cognitive decline, stand to benefit from the monoclonal antibodies. Burns predicts that if a benefit is substantiated, there will be a major paradigm shift in screening for Alzheimer's disease. 'It could be coming quickly if the trials of the new drugs work to reduce risk in this population. And if they do, then we will be in a whole different world. Then everyone over 65 should be screened.' That said, amyloid is not the whole story on preventing or delaying Alzheimer's onset. It's an early feature, but removing amyloid only slows, not stops, the disease. 'The focus now is can we stop or slow tau from accumulating?' Burns explains. Tau is a protein that builds up in dead or dying neurons in Alzheimer's disease, and it spreads through the brain. First the amyloid buildup starts, and appears to accelerate the tau. 'So pulling the amyloid out looks like it slows the tau accumulation, but doesn't stop it,' says Burns. An experimental drug in phase 2 clinical trials uses a new approach to reduce the accumulation of tau. 'The tau comes much later than the amyloid,' explains Donna Wilcock, Director of the Center for Neurodegenerative Disorders at Indiana University School of Medicine. 'Amyloid usually precedes the detection of tangle pathology by maybe 10 years. So we may have a 10-year window of catching that amyloid before it starts downstream tau.' In the last decade, researchers have learned that there is a tipping point at which the tau pathology is self-propagating, and the presence or absence of amyloid doesn't affect the tau – dubbed the 'cataustrophe.' 'It seems as though the earlier we can get these amyloid-lowering therapies into patients,' Wilcock says, 'the better the outcome.' What You Can Do To Lower Risk All the experts interviewed for this article stressed the importance of healthy lifestyle habits, which may prevent up to 45.3% of all dementia cases according to the Lancet Commission. These factors are essential: controlling hypertension, blood sugar, and cholesterol, getting regular exercise and seven to eight hours of quality sleep, having an active social life, and eating a largely plant-based Mediterranean diet. 'Controlling a lot of these factors in the mid-life period has the biggest impact on how they affect your risk for dementia later in life,' says Wilcock. 'Mid-life untreated hypertension greatly increases your risk for dementia later in life.' Her own blood pressure started rising in her 40s, and she pushed her primary care doctor to manage it aggressively, noting that she had to 'self-advocate' to get her doctor to take it seriously. 'Through better brain health and attention to modifiable risk factors, how can we eliminate half of dementia before it ever starts?' asks Greg Cooper. 'And for other half, how can we identify it and successfully intervene before we ever have symptoms? It may sound hyperbolic, but I can at least imagine that day.' Jeff Burns concurs that it's an optimistic time for the field, with a broader array of approaches in development than ever before. As of 2023, there were over 140 drugs in clinical trials for Alzheimer's. For patients like Jerry Klauer, breakthrough science is already a clinical reality. Such encouraging experiences and the rapid pace of advancements over the last few years gives me great hope that one day, this terrible disease itself will be long you to Kira Peikoff for additional research and reporting on this article.
